Coronary Plaque Burden on Coronary Computed Tomographic Angiography in Diabetics Versus Non-Diabetics

Delicce, Anthony; Alawneh, Basem; D'Angelo, Kyla; Bass, David I.; Hai, Ofek; Chikvashvili, Daniel; Zeltser, Roman; Makaryus, Amgad N.

doi:10.1016/s0735-1097(18)32168-5

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For patients with HFrEF to yield an adequate SV and cardiac output, they require a sizeable end-diastolic volume [ 9 ]. However, reduced left ventricular contractility in heart failure leads to reduced elastic recoil and abnormal filling, causing a downward shift in the Frank-Starling curve [ 19 ] (Figure 3 ). This results in a decreased SV and compensatory increase in end-diastolic pressure due to incomplete ventricular emptying.…”

Section: Reviewmentioning

confidence: 99%

“…These medications inhibit the RAAS, reducing vasoconstriction and afterload and ultimately improving cardiac function. Clinical trials, such as the large European study BIOSTAT-CHF, have shown the importance of appropriate dosing, significantly reducing cardiovascular mortality and hospitalization [ 19 ]. However, some patients experience side effects such as cough or angioedema, which may limit the tolerability and efficacy of ACEi drugs, even when appropriately dosed.…”

Section: Reviewmentioning

confidence: 99%

“…ARNIs combine RAAS inhibition with the prevention of natriuretic peptide degradation, providing a dual mechanism for improved cardiac function. Studies have demonstrated a significant reduction in cardiovascular mortality, overall mortality, and heart failure-related hospitalizations with sacubitril/valsartan therapy compared to ACEi treatment [ 19 , 31 ]. However, being a newer class of medication, long-term safety, and tolerability data may still be evolving.…”

Section: Reviewmentioning

confidence: 99%

See 2 more Smart Citations

The Pathophysiology and New Advancements in the Pharmacologic and Exercise-Based Management of Heart Failure With Reduced Ejection Fraction: A Narrative Review

Narayan,

Terre,

Amin

et al. 2023

Cureus

View full text Add to dashboard Cite

Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome whose management has significantly evolved based on the pathophysiology and disease process. It is widely prevalent, has a relatively high mortality rate, and is comparatively more common in men than women. In HFrEF, the series of maladaptive processes that occur lead to an inability of the muscle of the left ventricle to pump blood efficiently and effectively, causing cardiac dysfunction. The neurohormonal and hemodynamic adaptations play a significant role in the advancement of the disease and are critical to guiding the treatment and management of HFrEF. The first-line therapy, which includes loop diuretics, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, hydralazine/isosorbide-dinitrate, and mineralocorticoid receptor antagonists (MRAs), has been proven to provide symptomatic relief and decrease mortality and complications. The newly recommended drugs for guideline-based therapy, angiotensin receptor/neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 inhibitors, soluble guanylate cyclase, and myosin activators and modulators have also been shown to improve cardiac function, reverse cardiac remodeling, and reduce mortality rates. Recent studies have demonstrated that exercise-based therapy has resulted in an improved quality of life, exercise capacity, cardiac function, and decreased hospital readmission rates, but it has not had a considerable reduction in mortality rates. Combining multiple therapies alongside holistic advances such as exercise therapy may provide synergistic benefits, ultimately leading to improved outcomes for patients with HFrEF. Although first-line treatment, novel pharmacologic management, and exercise-based therapy have been shown to improve prognosis, the existing literature suggests a need for further studies evaluating the long-term effects of MRA and ARNI.

show abstract

Section: Reviewmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%